News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Daniel J. George, MD, Duke Cancer Institute

Articles by Daniel J. George, MD, Duke Cancer Institute

Emerging Therapies for Advanced Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Radium-223 in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Genetic Testing in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Impact of Clinical Data on the Treatment of mCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

The CARD and PROfound Trials for Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Differences Between AR-Targeted Therapy in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Overall Survival Data Presented at ASCO 2020 for nmCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

FDA Approved Agents for Non-Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Clinical Trials in the Community Setting for Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Data for Metastatic Castration-Sensitive Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Conventional Versus PSMA Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

PSMA-Targeted Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Latest Updated Articles

FDA Approved Agents for Non-Metastatic CRPC
Published: July 9th 2020 | Updated:
Conventional Versus PSMA Imaging in Prostate Cancer
Published: July 9th 2020 | Updated:
The CARD and PROfound Trials for Metastatic CRPC
Published: July 9th 2020 | Updated:
Emerging Therapies for Advanced Prostate Cancer
Published: July 9th 2020 | Updated:
Data for Metastatic Castration-Sensitive Prostate Cancer
Published: July 9th 2020 | Updated:
Impact of Clinical Data on the Treatment of mCRPC
Published: July 9th 2020 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma